Diafiltration flowrate is a determinant of the extent of adsorption of amikacin in renal replacement therapy using the ST150 ® -AN69 filter: An in vitro study
Restricted accessResearch articleFirst published online December, 2020
Diafiltration flowrate is a determinant of the extent of adsorption of amikacin in renal replacement therapy using the ST150 ® -AN69 filter: An in vitro study
In continuous renal replacement therapy, conduction and convection are controlled allowing prescribing dosage regimen improving survival. In contrast, adsorption is an uncontrolled property altering drug disposition. Whether adsorption depends on flowrates is unknown. We hypothesized an in vitro model may provide information in conditions mimicking continuous renal replacement therapy in humans.
Methods:
ST150®-AN69 filter and Prismaflex dialyzer, Baxter-Gambro were used. Simulated blood flowrate was set at 200 mL/min. The flowrates in the filtration (continuous filtration), dialysis (continuous dialysis), and diafiltration (continuous diafiltration) were 1500, 2500, and 4000 mL/h, respectively. Routes of elimination were assessed using NeckEpur® analysis.
Results:
The percentages of the total amount eliminated by continuous filtration, continuous dialysis, and continuous diafiltration were 82%, 86%, and 94%, respectively. Elimination by effluents and adsorption accounted for 42% ± 7% and 58% ± 5%, 57% ± 7% and 43% ± 6%, and 84% ± 6% and 16% ± 6% of amikacin elimination, respectively. There was a linear regression between flowrates and amikacin clearance: Y = 0.6 X ± 1.7 (R2 = 0.9782). Conversely, there was a linear inverse correlation between the magnitude of amikacin adsorption and flowrate: Y = –16.9 X ± 84.1 (R2 = 0.9976).
Conclusion:
Low flowrates resulted in predominant elimination by adsorption, accounting for 58% of the elimination of amikacin from the central compartment in the continuous filtration mode at 1500 mL/h of flowrate. Thereafter, the greater the flowrate, the lower the adsorption of amikacin in a linear manner. Flowrate is a major determinant of adsorption of amikacin. There was an about 17% decrease in the rate of adsorption per increase in the flowrate of 1 L/min.
RogerCWallisSCMullerL, et al. Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother2016; 60(8): 4901–4909.
2.
ChambersHSandeM. The aminoglycosides. In: HardmanJLimbirdLMolinoffP, et al. (eds) Goodman’s & Gilman’s the pharmacological basis of therapeutics. 9th ed.New York: McGraw-Hill, 1996, pp. 1103–1121.
3.
KronfolNOLauAHBarakatMM. Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. ASAIO Trans1987; 33(3): 300–303.
4.
RowlandMTozerTN. Dialysis. In: RowlandMTozerTN (eds) Clinical pharmacokinetics: concepts and applications. 3rd ed.Baltimore, MD: Lippincott Williams & Wilkins, 1995, pp. 443–462.
5.
PurohitPJElkomyMHFrymoyerA, et al. Antimicrobial disposition during pediatric continuous renal replacement therapy using an ex vivo model. Crit Care Med2019; 47: e767–e773.
6.
SchetzM. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care2007; 13(6): 645–651.
7.
BaudFJJullienVSecrétanP-H, et al. Are we correctly treating invasive candidiasis under continuous renal replacement therapy with echinocandins? Preliminary in vitro assessment. Anaesth Crit Care Pain Med. Epub ahead of print 3April2020. DOI: 10.1016/j.accpm.2020.01.007
8.
BrasseurAHitesMRoisinS, et al. A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. J Antimicrob Chemother2016; 71(5): 1386–1394.
9.
D’ArcyDMCaseyEGowingCM, et al. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. BMC Pharmacol Toxicol2012; 13: 14.
10.
LamPTianQIpM, et al. In vitro adsorption of gentamicin and netilmicin by polyacrylonitrile and polyamide hemofiltration filters. Antimicrob Agents Chemother2010; 54(2): 963–965.
11.
RimmeleTKellumJA. High-volume hemofiltration in the intensive care unit: a blood purification therapy. Anesthesiology2012; 116(6): 1377–1387.
12.
HouzéPBaudFJRaphalenJH, et al. Continuous renal replacement therapy in the treatment of severe hyperkalemia: an in vitro study. Int J Artif Organs2020; 43: 87–93.
13.
NeriMVillaGGarzottoF, et al. Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care2016; 20(1): 318.
14.
RowlandMTozerTN. Intravenous dose. In: RowlandMTozerTN (eds) Clinical pharmacokinetics: concepts and applications. 3rd ed.Baltimore, MD: Lippincott Williams & Wilkins, 1995, pp. 18–33.
15.
HouzéPLaforgeMBaudFJ. Lactate blood measurement in acute cyanide poisoning: effect of preanalytical delay and hydroxocobalamin uses as treatment. Ann Biol Clin2018; 76(1): 96–103.
16.
ChaijamornWShawARLewisSJ, et al. Ex vivo ceftolozane/tazobactam clearance during continuous renal replacement therapy. Blood Purif2017; 44(1): 16–23.
17.
RumpfKWRiegerJAnsorgR, et al. Binding of antibiotics by dialysis membranes and its clinical relevance. Proc Eur Dial Transplant Assoc1977; 14: 607–609.
18.
ChoiGGomersallCDLipmanJ, et al. The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration an in vitro study of levofloxacin. Int J Antimicrob Agents2004; 24(5): 468–472.
19.
TianQGomersallCDIpM, et al. Effect of preexposure to aminoglycosides on in vitro adsorption of amikacin by polyacrylonitrile hemofilters. Antimicrob Agents Chemother2011; 55(7): 3641–3642.
20.
TianQGomersallCDIpM, et al. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother2008; 52(3): 1009–1013.
21.
TianQGomersallCDLeungPP, et al. The adsorption of vancomycin by polyacrylonitrile, polyamide, and polysulfone hemofilters. Artif Organs2008; 32(1): 81–84.
22.
TianQGomersallCDWongA, et al. Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. Int J Antimicrob Agents2006; 28(2): 147–150.
23.
SchroederTHKruegerWAHansenM, et al. Elimination of meropenem by continuous hemo(dia) filtration: an in vitro one-compartment model. Int J Artif Organs1999; 22(5): 307–312.
24.
JangSMCardoneKENolinTD, et al. Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system. BMC Nephrol2014; 15: 204.
25.
PhillipsGJDaviesJGOlliffCJ, et al. Use of in vitro models of haemofiltration and haemodiafiltration to estimate dosage regimens for critically ill patients prescribed cefpirome. J Clin Pharm Ther1998; 23(5): 353–359.
26.
ShiraishiYOkajimaMSaiY, et al. Elimination of teicoplanin by adsorption to the filter membrane during haemodiafiltration: screening experiments for linezolid, teicoplanin and vancomycin followed by in vitro haemodiafiltration models for teicoplanin. Anaesth Intensive Care2012; 40(3): 442–449.
27.
GolperTA. Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. Contrib Nephrol2001; 132: 349–353.
28.
KonigCRohrACFreyOR, et al. In vitro removal of anti-infective agents by a novel cytokine adsorbent system. Int J Artif Organs2019; 42: 57–64.
29.
BaudFJHouzéP. RE to manuscript “In vitro removal of anti-infective agents by a novel cytokine adsorbent system.”Int J Artif Organs2019; 42: 528–529.
30.
BaudFJHouzéPRaphalenJ-H, et al. Does pharmacokinetics in the central compartment evidence routes of elimination during continuous renal replacement therapy in ex vivo model?Crit Care Med2020; 48(2): e163–e164.
31.
SimeFBPandeySKaramujicN, et al. Ex vivo characterization of effects of renal replacement therapy modalities and settings on pharmacokinetics of meropenem and vaborbactam. Antimicrob Agents Chemother2018; 62(10): e01306–e01318.
32.
Mac-KayMVFernandezIPHerrera CarranzaJ, et al. An in vitro study of the influence of a drug’s molecular weight on its overall (Clt), diffusive (Cld) and convective (Clc) clearance through dialysers. Biopharm Drug Dispos1995; 16(1): 23–35.
33.
MaherJF. Principles of dialysis and dialysis of drugs. Am J Med1977; 62(4): 475–481.
34.
ManningMCPatelKBorchardtRT. Stability of protein pharmaceuticals. Pharm Res1989; 6(11): 903–918.
35.
ReidenbergMMOdar-CederlofIvon BahrC, et al. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med1971; 285(5): 264–267.
36.
PinnerNACanadaRBBroylesJE, et al. Evaluation of vancomycin and gentamicin dialysis clearance using in vivo and in vitro systems. Ren Fail2012; 34(6): 703–707.
37.
WongGBriscoeSMcWhinneyB, et al. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother2018; 73(11): 3087–3094.
38.
IgariYSugiyamaYAwazuS, et al. Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital, and thiopental in the rat. J Pharmacokinet Biopharm1982; 10(1): 53–75.
39.
PerrottetNRobatelCMeylanP, et al. Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. J Antimicrob Chemother2008; 61(6): 1332–1335.
40.
TsujiAYoshikawaTNishideK, et al. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: tissue distribution and elimination in rats. J Pharm Sci1983; 72(11): 1239–1252.
41.
MatthewDBrennanBZomorodiK, et al. Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. Pharm Res1993; 10(3): 418–422.
42.
SimanjuntakMTSatoHTamaiI, et al. Transport of the new quinolone antibacterial agents of lomefloxacin and ofloxacin by rat erythrocytes, and its relation to the nicotinic acid transport system. J Pharmacobiodyn1991; 14(8): 475–481.
43.
ColinoCIGarcia TurinoASanchez NavarroA, et al. A comparative study of ofloxacin and ciprofloxacin erythrocyte distribution. Biopharm Drug Dispos1998; 19(2): 71–77.
44.
ReinosoRFTelferBARowlandM. In vitro studies of teicoplanin binding to rat tissues and erythrocytes. Eur J Pharm Sci1998; 6(2): 145–152.
45.
BulliardCGuignardJ-PRuizJ, et al. Cinétique des transferts de potassium au cours de l’hémodialyse. Néphrologie2001; 22(1): 15–19.
46.
JamalJAUdyAAWallisSC, et al. Can we use an ex vivo continuous hemofiltration model to describe the adsorption and elimination of meropenem and piperacillin?Int J Artif Organs2015; 38(8): 419–424.
